Director, Medical Writing

Lyell Immunopharma

Where
USA
Pay
$220K to $240K a year

Posted 2 months ago· Checked live at Lyell Immunopharma 2 hours ago

Stale: open 76 daysUp for more than two weeks. It may already be filled.

See how you score for this job

One sentence and your resume. We score it against what Lyell Immunopharma asks for, line by line.

See my score
Is this job still open?
Yes. We checked it live on Lyell Immunopharma's own hiring page 2 hours ago.
What is the job?
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers.
What does it pay?
$220K to $240K a year, as the posting states.
Our verdict
Stale. Up for more than two weeks. It may already be filled.

What the job is

Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers.

Key Responsibilities

Clinical Document Ownership — Core of the Role

  • Lead author for protocols and amendments, working with Clinical Development, Biostatistics, Clinical Operations, and Safety to turn study design into clear, executable, regulator-ready text.
  • Own the Investigator’s Brochure lifecycle — annual updates, safety-driven revisions, and manufacturing or product changes — keeping the benefit-risk narrative accurate as the data set matures.
  • Author Clinical Study Reports to ICH E3 end-to-end: TLF shell review, data interpretation, draft cycles, comment resolution, and QC.
  • Author supporting documents: ICF templates, DSURs, clinical sections of annual reports, and synopses.

Preferred

  • Cell or gene therapy — CAR-T, TIL, TCR-T, or other engineered cell products.
  • Technical fluency to contribute to CMC documentation or prior Module 2.3 authorship; FDA briefing documents or advisory committee materials.
  • Accelerated pathways: RMAT, Breakthrough Therapy, Fast Track, Accelerated Approval, or Priority Review.
  • Implementing or governing AI-assisted authoring in a GxP or submission context — tool qualification, SOP development, data handling controls, or documentation of human review.
  • Structured content management or automated document assembly; EMA/PRIME or other ex-US submission requirements; AMWA or RAPS certification.

The salary range for this position is $220,000 to $240,000, annually, with the opportunity to earn an annual bonus. The salary range is an estimate, and the actual salary may vary based on Lyell’s compensation practices and an applicant’s qualifications and experience. Employees are also eligible to participate in Lyell’s Equity Incentive Plan.

At Lyell, we believe that highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse and inclusive culture for all employees. Lyell is proud to be an equal opportunity employer and does not discriminate on the basis of race, color, citizenship status, national origin, ancestry, sex, sexual orientation, age, religion, creed, physical or mental disability, medical condition, marital status, veteran status or any other characteristics protected under applicable federal, state and local laws.